Expert Comparison: Two Leading Weight Management Options
What Is The Difference Between Wegovy And Mounjaro: Mechanism Comparison
The fundamental difference between Wegovy and Mounjaro lies in their mechanisms of action, which determines how each treatment supports weight management. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a single natural hormone responsible for appetite regulation and promoting feelings of fullness after meals. This targeted approach works specifically on brain appetite centres to reduce food cravings and extend satiety between meals.
Mounjaro, conversely, contains tirzepatide, which functions as a dual agonist targeting both GIP and GLP-1 receptors simultaneously. This dual mechanism approach affects multiple pathways involved in glucose regulation and appetite control, representing a different therapeutic strategy. Both treatments require prescription-only medicine status and must be used alongside a reduced-calorie diet and increased physical activity for optimal effectiveness.
Wegovy vs Mounjaro Pricing: Transparent Cost Comparison
Understanding what is the difference between Wegovy and Mounjaro extends to pricing structures, where EverydayMeds offers comprehensive options for both treatments. Wegovy follows a five-dose escalation schedule starting at £79.99 for the 0.25mg starter dose, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles, such as the Intro Duo (0.25mg & 0.5mg) at £169.99, provide convenient multi-dose packages with discount codes FIRST40 for new customers and DOSE25 for returning patients applied at checkout.
Mounjaro pricing follows its six-dose escalation pathway with different cost considerations, though both treatments represent significant investments in long-term weight management. Our bundles eliminate the need for frequent reordering whilst ensuring continuous supply during dose escalation phases. The Ultimate Stability Trio provides three months of maintenance Wegovy (2.4mg) supply for £649.99, offering convenience rather than savings compared to individual purchases.
Clinical Evidence: STEP Trials And Treatment Efficacy
When examining what is the difference between Wegovy and Mounjaro, clinical trial evidence provides crucial context, though direct comparisons require careful interpretation due to different study designs and populations. The STEP trial programme demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in STEP 1, with sustained results of 15.2% at two years in STEP 5. The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events, highlighting benefits beyond weight management.
Mounjaro's clinical evidence stems from different trial protocols with varying patient populations, making head-to-head percentage comparisons inappropriate without clinical context. Both treatments underwent rigorous MHRA evaluation before UK approval, with Wegovy receiving NICE TA875 recommendation for specialist weight management support. Your prescriber can evaluate which treatment's clinical profile aligns with your individual health circumstances and weight management goals.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy's semaglutide ingredient functions as a GLP-1 receptor agonist, mimicking the action of glucagon-like peptide-1, a hormone naturally produced in your intestines after eating. This mechanism reduces appetite by acting on brain appetite centres, particularly the hypothalamus, whilst slowing gastric emptying to promote prolonged feelings of fullness after smaller meals. The treatment may help reduce food cravings and decrease the frequency of eating episodes throughout the day. Clinical studies suggest this mechanism supports sustainable weight management when combined with lifestyle modifications. The once-weekly injection schedule using Novo Nordisk's FlexTouch pen system provides consistent hormone levels between doses. Understanding this mechanism helps explain why Wegovy must be used alongside reduced-calorie diet and increased physical activity for optimal effectiveness.
EverydayMeds Ordering Process: From Assessment To Delivery
Our streamlined process makes accessing both Wegovy and Mounjaro straightforward through our GPhC-registered pharmacy (#9012878). The journey begins with a comprehensive 3-minute online clinical assessment covering medical history, current medications, and weight management goals. Following submission, our qualified prescribers review applications within standard 3 working days, or 24 hours with express review options. Upon prescription approval, treatments ship via next-day cold-chain delivery maintaining the required 2-8°C temperature throughout transit. Each delivery includes detailed injection instructions, storage guidelines, and direct access to our clinical support team. This process ensures appropriate clinical oversight whilst providing convenient access to prescription-only medicines from the comfort of your home.
Storage And Practical Considerations: Wegovy Advantages
A significant practical difference between Wegovy and Mounjaro involves storage requirements, particularly for patients with active lifestyles or frequent travel commitments. Wegovy maintains stability for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This extended stability provides greater flexibility for holidays, business trips, or situations where refrigeration access becomes temporarily unavailable. Both treatments require initial storage at 2-8°C in refrigerator conditions, but Wegovy's extended room temperature tolerance offers practical advantages. The FlexTouch pen delivery system provides consistent dosing with clear visual indicators for remaining doses. Proper storage ensures treatment efficacy whilst the extended room temperature stability reduces anxiety about accidental temperature exposure during daily use.
Wegovy vs Mounjaro: Dose Escalation Comparison
The difference between Wegovy and Mounjaro becomes apparent in their respective dose escalation schedules, designed to minimise gastrointestinal side effects whilst achieving therapeutic effectiveness. Wegovy follows a five-step escalation over 16 weeks: starting with 0.25mg for weeks 1-4, advancing to 0.5mg (weeks 5-8), then 1mg (weeks 9-12), 1.7mg (weeks 13-16), before reaching the 2.4mg maintenance dose from week 17 onwards. This gradual progression allows your body to adapt to increasing semaglutide levels whilst monitoring tolerance and effectiveness.
Mounjaro employs a six-dose escalation pathway with different timing and dose increments, starting from 2.5mg and potentially reaching 15mg maintenance doses depending on individual response and tolerance. Both treatments prohibit dose skipping during escalation phases, as this graduated approach minimises adverse effects whilst optimising therapeutic outcomes. Your prescriber will determine the appropriate escalation schedule based on your response, tolerability, and weight management progress throughout treatment.
Both Available From EverydayMeds: Expert Prescriber Guidance
EverydayMeds' unique position as a supplier of both Wegovy and Mounjaro eliminates the need to research multiple pharmacy options when comparing these treatments. Our clinical team provides impartial guidance based on your individual circumstances rather than product availability constraints. Whether your prescriber determines Wegovy's GLP-1 mechanism or Mounjaro's dual agonist approach better suits your needs, we ensure seamless access through the same trusted ordering process. This comprehensive approach means you can focus on your weight management journey rather than navigating different suppliers, with consistent clinical support regardless of which treatment proves most appropriate. Both treatments arrive via the same cold-chain delivery system with identical storage instructions and ongoing support from our GPhC-registered pharmacy team (#9012878), ensuring continuity throughout your treatment experience.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
